Roger Deeley

PhD
Dr. Roger Deeley
613-549-6666 x.3344

Roles

 

  • Vice President, Health Sciences Research, KHSC and President & CEO, KGHRI
  • Vice-Dean, Research, Faculty of Health Sciences, Queen’s University

Interests

Cancer, multidrug resistance, gene expression

 

Bio

Following 10 years with the National Cancer Institute at the National Institutes of Health in the United States, Dr. Deeley came to Queen’s University in 1980. He was promoted to the rank of Professor in 1984 and in 1987 he was appointed as the first holder of the Joseph S. Stauffer Chair and as Director of the Cancer Research Laboratories. He served as Director of the Division of Research for Cancer Care Ontario from 1988 to 2007 and since 2003 he has also been the Director of Queen’s Cancer Research Institute. Dr. Deeley has held the joint position of Vice-Dean Research in the Faculty of Health Sciences and Vice President Health Sciences Research at Kingston General Hospital since 2007. He is a member of the Department of Pathology and Molecular Medicine with cross-appointments in the Department of Biomedical and Molecular Sciences and the Department of Oncology.

Dr. Deeley’s research program has been extensively cited internationally and  funded from sources such as the Canadian Institutes of Health Research, the National Cancer Institute of Canada, the Heart and Stroke Foundation of Ontario, and industry. He has also been responsible for developing a number of major research initiatives, which together with his own research program, have garnered over $32M in funding. Dr. Deeley has extensive experience with research funding agencies and has been involved in both provincial and national cancer control research agendas. In 2005, he was co-recipient of the Robert L. Noble Prize presented jointly by the National Cancer Institute of Canada and the Canadian Cancer Society, and in 2007 he was a recipient of the National Cancer Institute of Canada’s Diamond Jubilee Award for outstanding contributions to cancer research.

 

Education and honours

  • BSC University of Sheffield
  • PhD University of Sheffield
  • Fogarty International Fellowship, US National Institutes of Health  
  • Fellow, Canadian Academy of Health Sciences
  • Fellow, Royal Society of Canada
  • Robert L. Noble Prize of the Canadian Cancer Society
  • National Cancer Institute of Canada’s Diamond Jubilee Award

 

Research

Dr. Deeley has conducted pioneering work in the molecular biology of cancer.  His early investigations resulted in novel approaches to gene cloning, and laid the foundation for his subsequent breakthrough discovery, with Queen’s co-investigator Dr. Susan Cole, of the gene coding for a multidrug resistance protein (MRP). Their groundbreaking work represented a significant advancement in scientific understanding of why some patients developed resistance to drugs used to treat cancer and other diseases. 

Author of approximately 200 peer-reviewed publications and book chapters, and with more than 17,000 citations, Dr. Deeley is also a named inventor on 12 patents worldwide relating to this work, which continues to contribute significantly to drug development and cancer research.